Hims & Hers Health shares fell sharply after reporting a surprise first-quarter loss and revenue that missed expectations. The company, however, raised its full-year revenue outlook and signaled stronger second-quarter sales. The stock reaction underscores how investors are weighing results against ongoing regulatory scrutiny tied to weight-loss drugs and pricing momentum.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
